

# Gerhard GrÃ¼nder

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9591073/publications.pdf>

Version: 2024-02-01

201  
papers

9,583  
citations

50170

46  
h-index

46693

89  
g-index

229  
all docs

229  
docs citations

229  
times ranked

9367  
citing authors

#	ARTICLE	IF	CITATIONS
1	Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. <i>Pharmacopsychiatry</i> , 2018, 51, 9-62.	1.7	787
2	AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. <i>Pharmacopsychiatry</i> , 2011, 44, 195-235.	1.7	774
3	Correlation between dopamine D(2) receptors in the ventral striatum and central processing of alcohol cues and craving. <i>American Journal of Psychiatry</i> , 2004, 161, 1783-9.	4.0	341
4	Anticipation of monetary and social reward differently activates mesolimbic brain structures in men and women. <i>Social Cognitive and Affective Neuroscience</i> , 2009, 4, 158-165.	1.5	336
5	Dissociation of neural networks for anticipation and consumption of monetary and social rewards. <i>NeuroImage</i> , 2010, 49, 3276-3285.	2.1	273
6	Dopamine D2 and D3 Receptor Occupancy in Normal Humans Treated with the Antipsychotic Drug Aripiprazole (OPC 14597) A Study Using Positron Emission Tomography and [ <sup>11</sup> C]Raclopride. <i>Neuropsychopharmacology</i> , 2002, 27, 248-259.	2.8	261
7	Correlation of Alcohol Craving With Striatal Dopamine Synthesis Capacity and D2/3Receptor Availability: A Combined [ <sup>18</sup> F]DOPA and [ <sup>18</sup> F]DMFP PET Study in Detoxified Alcoholic Patients. <i>American Journal of Psychiatry</i> , 2005, 162, 1515-1520.	4.0	253
8	Oxytocin Influences Processing of Socially Relevant Cues in the Ventral Tegmental Area of the Human Brain. <i>Biological Psychiatry</i> , 2013, 74, 172-179.	0.7	205
9	Mechanism of New Antipsychotic Medications. <i>Archives of General Psychiatry</i> , 2003, 60, 974.	13.8	200
10	Association of Low Striatal Dopamine D <sub>2</sub> Receptor Availability With Nicotine Dependence Similar to That Seen With Other Drugs of Abuse. <i>American Journal of Psychiatry</i> , 2008, 165, 507-514.	4.0	189
11	Oxytocin plasma concentrations after single intranasal oxytocin administration – A study in healthy men. <i>Neuropeptides</i> , 2012, 46, 211-215.	0.9	186
12	The Role of Imaging in Proof of Concept for CNS Drug Discovery and Development. <i>Neuropsychopharmacology</i> , 2009, 34, 187-203.	2.8	161
13	The thalamus as the generator and modulator of EEG alpha rhythm: a combined PET/EEG study with lorazepam challenge in humans. <i>NeuroImage</i> , 2004, 22, 637-644.	2.1	160
14	Dopamine in amygdala gates limbic processing of aversive stimuli in humans. <i>Nature Neuroscience</i> , 2008, 11, 1381-1382.	7.1	150
15	Elevated [ <sup>18</sup> F]Fluorodopamine Turnover in Brain of Patients with Schizophrenia: An [ <sup>18</sup> F]Fluorodopa/Positron Emission Tomography Study. <i>Journal of Neuroscience</i> , 2007, 27, 8080-8087.	1.7	149
16	Brain and Plasma Pharmacokinetics of Aripiprazole in Patients With Schizophrenia: An [ <sup>18</sup> F]Fallypride PET Study. <i>American Journal of Psychiatry</i> , 2008, 165, 988-995.	4.0	139
17	The 'atypicality' of antipsychotics: a concept re-examined and re-defined. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 197-202.	21.5	125
18	Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology - a double-blind controlled study comparing a selective D <sub>2</sub> -like antagonist to a mixed D <sub>1</sub> -/D <sub>2</sub> -like antagonist. <i>Psychopharmacology</i> , 1998, 137, 223-232.	1.5	122

#	ARTICLE	IF	CITATIONS
19	Impaired sleep quality and sleep duration in smokersâ€™ results from the German Multicenter Study on Nicotine Dependence. <i>Addiction Biology</i> , 2014, 19, 486-496.	1.4	116
20	Anxiety is associated with reduced central serotonin transporter availability in unmedicated patients with unipolar major depression: a [11C]DASB PET study. <i>Molecular Psychiatry</i> , 2008, 13, 606-613.	4.1	113
21	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. <i>Pharmacopsychiatry</i> , 2022, 55, 73-86.	1.7	107
22	Subchronic Haloperidol Downregulates Dopamine Synthesis Capacity in the Brain of Schizophrenic Patients In Vivo. <i>Neuropsychopharmacology</i> , 2003, 28, 787-794.	2.8	105
23	Therapeutic Monitoring of New Antipsychotic Drugs. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 156-160.	1.0	105
24	TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 162-174.	1.3	103
25	A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. <i>Journal of Psychiatric Research</i> , 1996, 30, 441-451.	1.5	98
26	The Striatal and Extrastriatal D2/D3 Receptor-Binding Profile of Clozapine in Patients with Schizophrenia. <i>Neuropsychopharmacology</i> , 2006, 31, 1027-1035.	2.8	96
27	Differential patterns of nucleus accumbens activation during anticipation of monetary and social reward in young and older adults. <i>Social Cognitive and Affective Neuroscience</i> , 2014, 9, 825-831.	1.5	92
28	Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	1.1	86
29	Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance. <i>Frontiers in Psychiatry</i> , 2020, 11, 5.	1.3	84
30	Modulation of [18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge. <i>NeuroImage</i> , 2006, 30, 1332-1339.	2.1	71
31	â€œPrefrontalâ€™ cognitive performance of healthy subjects positively correlates with cerebral FDOPA influx: An exploratory [18F]-fluoro-L-DOPA-PET investigation. <i>Human Brain Mapping</i> , 2007, 28, 931-939.	1.9	71
32	Neuroendocrine response to antipsychotics: effects of drug type and gender. <i>Biological Psychiatry</i> , 1999, 45, 89-97.	0.7	66
33	Asymmetry in dopamine D2/3 receptors of caudate nucleus is lost with age. <i>NeuroImage</i> , 2007, 34, 870-878.	2.1	65
34	Cariprazine, a new, orally active dopamine D <sub>2/3</sub> receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 1141-1159.	1.4	63
35	Parametric mapping of binding in human brain of D2 receptor ligands of different affinities. <i>Journal of Nuclear Medicine</i> , 2005, 46, 964-72.	2.8	61
36	Schizophrenia risk polymorphisms in the <i>TCF4</i> gene interact with smoking in the modulation of auditory sensory gating. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 6271-6276.	3.3	60

#	ARTICLE	IF	CITATIONS
37	AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. <i>Pharmacopsychiatry</i> , 2011, 44, 195-235.	1.7	59
38	Time Course of 5-HT <sub>2A</sub> Receptor Occupancy in the Human Brain after a Single Oral Dose of the Putative Antipsychotic Drug MDL 100,907 Measured by Positron Emission Tomography. <i>Neuropsychopharmacology</i> , 1997, 17, 175-185.	2.8	56
39	Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study. <i>Lancet Psychiatry</i> , 2016, 3, 717-729.	3.7	56
40	PET Studies of Net Bloodâ€”Brain Clearance of FDOPA to Human Brain: Age-Dependent Decline of [18F]Fluorodopamine Storage Capacity. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, 807-819.	2.4	55
41	Bithalamic Deep Brain Stimulation in Tourette Syndrome Is Associated with Reduction in Dopaminergic Transmission. <i>Biological Psychiatry</i> , 2009, 66, e15-e17.	0.7	55
42	Acute Alcohol Effects on Neuronal and Attentional Processing: Striatal Reward System and Inhibitory Sensory Interactions under Acute Ethanol Challenge. <i>Neuropsychopharmacology</i> , 2004, 29, 1527-1537.	2.8	54
43	The Impact of Dopamine on Aggression: An [ <sup>18</sup> F]-FDOPA PET Study in Healthy Males. <i>Journal of Neuroscience</i> , 2013, 33, 16889-16896.	1.7	51
44	High striatal occupancy of D <sub>2</sub> -like dopamine receptors by amisulpride in the brain of patients with schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2004, 7, 421-430.	1.0	50
45	Opioid Receptor PET Reveals the Psychobiologic Correlates of Reward Processing. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1257-1261.	2.8	48
46	Therapeutic Plasma Concentrations of Antidepressants and Antipsychotics: Lessons from PET Imaging. <i>Pharmacopsychiatry</i> , 2011, 44, 236-248.	1.7	48
47	Age-dependent decline of steady state dopamine storage capacity of human brain: An FDOPA PET study. <i>Neurobiology of Aging</i> , 2010, 31, 447-463.	1.5	47
48	[ <sup>18</sup> F]Fluoroethylflumazenil: a novel tracer for PET imaging of human benzodiazepine receptors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 1463-1470.	3.3	46
49	Striatal D <sub>2</sub> /D <sub>3</sub> Receptor Occupancy, Clinical Response and Side Effects with Amisulpride: An Iodine-123-Iodobenzamide SPET Study. <i>Pharmacopsychiatry</i> , 2008, 41, 169-175.	1.7	46
50	Serum concentrations of paliperidone versus risperidone and clinical effects. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 797-803.	0.8	43
51	Dopamine Autoreceptor Agonists in the Treatment of Schizophrenia and Major Depression*. <i>Pharmacopsychiatry</i> , 1992, 25, 254-260.	1.7	42
52	Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable. <i>European Neuropsychopharmacology</i> , 2006, 16, 233-240.	0.3	40
53	In Vivo Evidence of Deep Brain Stimulation-Induced Dopaminergic Modulation in Tourette's Syndrome. <i>Biological Psychiatry</i> , 2012, 71, e11-e13.	0.7	40
54	Effects of Smoking Cessation on Presynaptic Dopamine Function of Addicted Male Smokers. <i>Biological Psychiatry</i> , 2016, 80, 198-206.	0.7	40

#	ARTICLE	IF	CITATIONS
55	Striatal and Extrastriatal D2/D3-Receptor-Binding Properties of Ziprasidone. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 608-617.	0.7	38
56	Quantification of D2-like dopamine receptors in the human brain with 18F-desmethoxyfallypride. <i>Journal of Nuclear Medicine</i> , 2003, 44, 109-16.	2.8	37
57	The applicability of SRTM in [18F]fallypride PET investigations: Impact of scan durations. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2011, 31, 1958-1966.	2.4	35
58	Opiate-Induced Dopamine Release Is Modulated by Severity of Alcohol Dependence: An [18F]Fallypride Positron Emission Tomography Study. <i>Biological Psychiatry</i> , 2011, 70, 770-776.	0.7	34
59	Brain imaging research: Does the science serve clinical practice?. <i>International Review of Psychiatry</i> , 2007, 19, 541-558.	1.4	33
60	Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 951-960.	1.0	33
61	Dopamine and opioid systems adaptation in alcoholism revisited: Convergent evidence from positron emission tomography and postmortem studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 106, 141-164.	2.9	32
62	Body mass index (BMI) but not body weight is associated with changes in the metabolism of risperidone; A pharmacokinetics-based hypothesis. <i>Psychoneuroendocrinology</i> , 2016, 73, 9-15.	1.3	31
63	Sertraline in pregnancy – Therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood. <i>Journal of Affective Disorders</i> , 2017, 212, 1-6.	2.0	31
64	Increase in Serum Clomipramine Concentrations Caused by Valproate. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 493-494.	0.7	31
65	Roxindole, a dopamine autoreceptor agonist, in the treatment of major depression. <i>Psychopharmacology</i> , 1993, 111, 123-126.	1.5	30
66	Long-Term Effects of the Substituted Benzamide Derivative Amisulpride on Baseline and Stimulated Prolactin Levels. <i>Neuropsychobiology</i> , 2002, 46, 33-40.	0.9	30
67	The P300 event-related potential and smoking – A population-based case-control study. <i>International Journal of Psychophysiology</i> , 2010, 77, 166-175.	0.5	30
68	Neural correlates of naturalistic social cognition: brain-behavior relationships in healthy adults. <i>Social Cognitive and Affective Neuroscience</i> , 2016, 11, 1741-1751.	1.5	30
69	Neural evidence for an association between social proficiency and sensitivity to social reward. <i>Social Cognitive and Affective Neuroscience</i> , 2014, 9, 661-670.	1.5	29
70	Effect of fluvoxamine augmentation and smoking on clozapine serum concentrations. <i>Schizophrenia Research</i> , 2019, 210, 143-148.	1.1	29
71	Disparate effects of first and second generation antipsychotics on cognition in schizophrenia – Findings from the randomized NeSSy trial. <i>European Neuropsychopharmacology</i> , 2019, 29, 720-739.	0.3	29
72	Elevated [18F]FDOPA utilization in the periaqueductal gray and medial nucleus accumbens of patients with early Parkinson's disease. <i>NeuroImage</i> , 2010, 49, 2933-2939.	2.1	28

#	ARTICLE	IF	CITATIONS
73	Pharmacokinetic Drug-Drug Interactions of Mood Stabilizers and Risperidone in Patients Under Combined Treatment. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 554-561.	0.7	28
74	Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial. <i>Schizophrenia Bulletin</i> , 2019, 45, 350-359.	2.3	28
75	In vitro affinities of various halogenated benzamide derivatives as potential radioligands for non-invasive quantification of D2-like dopamine receptors. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 6819-6829.	1.4	27
76	Effects of antipsychotic treatment on cognition in healthy subjects. <i>Journal of Psychopharmacology</i> , 2013, 27, 374-385.	2.0	27
77	Baseline [ <sup>18</sup> F]-FDOPA kinetics are predictive of haloperidol-induced changes in dopamine turnover and cognitive performance: A positron emission tomography study in healthy subjects. <i>NeuroImage</i> , 2008, 40, 1222-1231.	2.1	26
78	Vulnerability to psychotogenic effects of ketamine is associated with elevated D2/3-receptor availability. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 745-754.	1.0	25
79	Pharmacokinetic patterns of risperidone-associated adverse drug reactions. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 1091-1098.	0.8	25
80	Effects of alexithymia and empathy on the neural processing of social and monetary rewards. <i>Brain Structure and Function</i> , 2017, 222, 2235-2250.	1.2	25
81	Subchronic Antidepressant Treatment with Venlafaxine or Imipramine and Effects on Blood Pressure and Heart Rate: Assessment by Automatic 24-Hour Monitoring. <i>Pharmacopsychiatry</i> , 1996, 29, 72-78.	1.7	24
82	Impact of Different Antidopaminergic Mechanisms on the Dopaminergic Control of Prolactin Secretion. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 214-220.	0.7	24
83	P50 sensory gating and smoking in the general population. <i>Addiction Biology</i> , 2011, 16, 485-498.	1.4	24
84	Acute and Sustained Effects of Methylphenidate on Cognition and Presynaptic Dopamine Metabolism: An [ <sup>18</sup> F]FDOPA PET Study. <i>Journal of Neuroscience</i> , 2014, 34, 14769-14776.	1.7	24
85	The German multi-centre study on smoking-related behavior—description of a population-based case-control study. <i>Addiction Biology</i> , 2011, 16, 638-653.	1.4	23
86	Neural activation during anticipation of opposite-sex and same-sex faces in heterosexual men and women. <i>NeuroImage</i> , 2013, 66, 223-231.	2.1	23
87	Molecular imaging of schizophrenia: Neurochemical findings in a heterogeneous and evolving disorder. <i>Behavioural Brain Research</i> , 2021, 398, 113004.	1.2	23
88	Therapeutic Drug Monitoring of Long-Acting Injectable Antipsychotic Drugs. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 79-102.	1.0	23
89	Pregnancy exposure to citalopram — Therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 79, 213-219.	2.5	22
90	Pharmacokinetics of risperidone in different application forms — Comparing long-acting injectable and oral formulations. <i>European Neuropsychopharmacology</i> , 2018, 28, 130-137.	0.3	22

#	ARTICLE	IF	CITATIONS
91	Antidepressants in breast milk; comparative analysis of excretion ratios. Archives of Women's Mental Health, 2019, 22, 383-390.	1.2	22
92	Surrogate markers for cerebral blood flow correlate with [ <sup>18</sup> F]flallypride binding potential at dopamine D <sub>2/3</sub> receptors in human striatum. Synapse, 2013, 67, 199-203.	0.6	21
93	Effect of smoking on risperidone pharmacokinetics – A multifactorial approach to better predict the influence on drug metabolism. Schizophrenia Research, 2017, 185, 51-57.	1.1	21
94	Is There an Advantage to Venlafaxine in Comparison with Other Antidepressants?. Human Psychopharmacology, 1997, 12, 53-64.	0.7	20
95	Serotonergic modulation of response inhibition and reengagement? Results of a study in healthy human volunteers. Human Psychopharmacology, 2010, 25, 472-480.	0.7	20
96	Risperidone-induced extrapyramidal side effects. International Clinical Psychopharmacology, 2016, 31, 259-264.	0.9	20
97	Comparison of Clomethiazole and Diazepam in the Treatment of Alcohol Withdrawal Syndrome in Clinical Practice. European Addiction Research, 2017, 23, 211-218.	1.3	20
98	Comprehensive Measurements of Intrauterine and Postnatal Exposure to Lamotrigine. Clinical Pharmacokinetics, 2019, 58, 535-543.	1.6	20
99	Occupancy of striatal D <sub>2</sub> -like dopamine receptors after treatment with the sigma ligand EMD 57445, a putative atypical antipsychotic. Psychopharmacology, 1999, 146, 81-86.	1.5	19
100	Antipsychotic effects and tolerability of the sigma ligand EMD 57445 (pamamesine) and its metabolites in acute schizophrenia: an open clinical trial. Psychiatry Research, 1999, 89, 275-280.	1.7	19
101	Anterior limbic alpha-like activity: a low resolution electromagnetic tomography study with lorazepam challenge. Clinical Neurophysiology, 2005, 116, 886-894.	0.7	19
102	Remission of Drug-Induced Hepatitis After Switching from Risperidone to Paliperidone. American Journal of Psychiatry, 2010, 167, 351-352.	4.0	19
103	Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients – thinking of clinically relevant CYP2D6 interactions. Journal of Psychopharmacology, 2016, 30, 803-809.	2.0	19
104	Reduced serotonin transporter availability in patients with unipolar major depression reflect the level of anxiety. Molecular Psychiatry, 2008, 13, 557-557.	4.1	18
105	Reduced clearance of venlafaxine in a combined treatment with quetiapine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 85, 116-121.	2.5	18
106	Editorial to Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology. Pharmacopsychiatry, 2018, 51, 5-6.	1.7	18
107	Human dopamine receptor D <sub>2</sub> /D <sub>3</sub> availability predicts amygdala reactivity to unpleasant stimuli. Human Brain Mapping, 2010, 31, 716-726.	1.9	17
108	The use of ziprasidone in clinical practice: Analysis of pharmacokinetic and pharmacodynamic aspects from data of a drug monitoring survey. European Psychiatry, 2009, 24, 143-148.	0.1	17



#	ARTICLE	IF	CITATIONS
109	â€œAbsoluteâ€ or â€œrelativeâ€ Choosing the right outcome measure in neuroimaging. <i>NeuroImage</i> , 2009, 45, 258-259.	2.1	17
110	Functional Polymorphism in the Neuropeptide Y Gene Promoter (rs16147) Is Associated with Serum Leptin Levels and Waist-Hip Ratio in Women. <i>Annals of Nutrition and Metabolism</i> , 2013, 62, 271-276.	1.0	17
111	Effects of anticholinergic challenge on psychopathology and cognition in drug-free patients with schizophrenia and healthy volunteers. <i>Psychopharmacology</i> , 2015, 232, 1607-1617.	1.5	17
112	Naming for Psychotropic Drugs: Dilemma and Challenge. <i>Pharmacopsychiatry</i> , 2017, 50, 1-2.	1.7	17
113	Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain) <i>Tj ETQq1 1 0.784314 rgBT /Overlock</i> <i>Psychiatry</i> , 2021, 22, 561-628.	1.3	17
114	Therapeutic Reference Ranges for Psychotropic Drugs: A Protocol for Systematic Reviews. <i>Frontiers in Psychiatry</i> , 2021, 12, 787043.	1.3	17
115	Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression. <i>Current Opinion in Investigational Drugs</i> , 2010, 11, 823-32.	2.3	17
116	Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole. <i>International Journal of Neuropsychopharmacology</i> , 2007, 10, 149.	1.0	16
117	Genetic Variation in the Neuropeptide Y Gene Promoter Is Associated with Increased Risk of Tobacco Smoking. <i>European Addiction Research</i> , 2012, 18, 246-252.	1.3	16
118	The role of 5-HT in response inhibition and re-engagement. <i>European Neuropsychopharmacology</i> , 2013, 23, 830-841.	0.3	16
119	The role of striatal dopamine D2/3 receptors in cognitive performance in drug-free patients with schizophrenia. <i>Psychopharmacology</i> , 2018, 235, 2221-2232.	1.5	16
120	Antidepressant polypharmacy and the potential of pharmacokinetic interactions: Doxepin but not mirtazapine causes clinically relevant changes in venlafaxine metabolism. <i>Journal of Affective Disorders</i> , 2018, 227, 506-511.	2.0	16
121	Differences in Duloxetine Dosing Strategies in Smoking and Nonsmoking Patients. <i>Journal of Clinical Psychiatry</i> , 2018, 79, .	1.1	16
122	Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers. <i>Psychopharmacology</i> , 2011, 218, 733-748.	1.5	15
123	Pregnancy exposure to quetiapine â€“ Therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood and obstetrical outcomes. <i>Schizophrenia Research</i> , 2018, 195, 252-257.	1.1	15
124	Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine. <i>Clinical Pharmacokinetics</i> , 2018, 57, 729-737.	1.6	14
125	Increased Turnover of Dopamine in Caudate Nucleus of Detoxified Alcoholic Patients. <i>PLoS ONE</i> , 2013, 8, e73903.	1.1	13
126	Evaluation of P-glycoprotein (abcb1a/b) modulation of [18F]fallypride in MicroPET imaging studies. <i>Neuropharmacology</i> , 2014, 84, 152-158.	2.0	13



#	ARTICLE	IF	CITATIONS
127	Clinical response in a risperidone-medicated naturalistic sample: patients' characteristics and dose-dependent pharmacokinetic patterns. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 325-333.	1.8	13
128	Body mass index as a determinant of clozapine plasma concentrations: A pharmacokinetic-based hypothesis. <i>Journal of Psychopharmacology</i> , 2021, 35, 273-278.	2.0	13
129	Tiagabine does not attenuate alcohol-induced activation of the human reward system. <i>Psychopharmacology</i> , 2007, 191, 975-983.	1.5	12
130	Impact of personal economic environment and personality factors on individual financial decision making. <i>Frontiers in Psychology</i> , 2014, 5, 158.	1.1	12
131	Measuring citalopram in blood and central nervous system. <i>International Clinical Psychopharmacology</i> , 2016, 31, 119-126.	0.9	12
132	Sex and body weight are major determinants of venlafaxine pharmacokinetics. <i>International Clinical Psychopharmacology</i> , 2018, 33, 322-329.	0.9	12
133	The Potential Role of Psychedelic Drugs in Mental Health Care of the Future. <i>Pharmacopsychiatry</i> , 2021, 54, 191-199.	1.7	12
134	Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) – Rationale and study design. , 2022, 1, 100104.		12
135	Dopamine D2/D3 receptor availability and venturesomeness. <i>Psychiatry Research - Neuroimaging</i> , 2011, 193, 80-84.	0.9	11
136	Cytochrome P450-mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1668-1675.	1.1	11
137	Enhancement of atomoxetine serum levels by co-administration of paroxetine. <i>International Journal of Neuropsychopharmacology</i> , 2008, 11, 289-91.	1.0	10
138	Suicide Attempt During Late Pregnancy With Quetiapine. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 343-344.	0.7	10
139	Pharmacokinetic Interaction Between Valproic Acid, Meropenem, and Risperidone. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 90-92.	0.7	10
140	Dopamine D2 Receptor Occupancy Estimated From Plasma Concentrations of Four Different Antipsychotics and the Subjective Experience of Physical and Mental Well-Being in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 550-560.	0.7	10
141	Pregnancy exposure to venlafaxine – Therapeutic drug monitoring in maternal blood, amniotic fluid and umbilical cord blood and obstetrical outcomes. <i>Journal of Affective Disorders</i> , 2020, 266, 578-584.	2.0	10
142	Tranlycypromine Abuse Associated With Delirium and Thrombocytopenia. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 270-271.	0.7	10
143	Influence of Kidney Function on Serum Risperidone Concentrations in Patients Treated With Risperidone. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	1.1	10
144	Molecular Imaging of Dopamine Partial Agonists in Humans: Implications for Clinical Practice. <i>Frontiers in Psychiatry</i> , 2022, 13, 832209.	1.3	10

#	ARTICLE	IF	CITATIONS
145	Effects of psychotropic drugs on brain plasticity in humans. <i>Restorative Neurology and Neuroscience</i> , 2014, 32, 163-181.	0.4	9
146	Lamotrigine in pregnancy – therapeutic drug monitoring in maternal blood, amniotic fluid, and cord blood. <i>International Clinical Psychopharmacology</i> , 2015, 30, 249-254.	0.9	9
147	Distribution pattern of mirtazapine and normirtazapine in blood and CSF. <i>Psychopharmacology</i> , 2015, 232, 807-813.	1.5	9
148	Association of Common Polymorphisms in the Nicotinic Acetylcholine Receptor Alpha4 Subunit Gene with an Electrophysiological Endophenotype in a Large Population-Based Sample. <i>PLoS ONE</i> , 2016, 11, e0152984.	1.1	9
149	How to Treat Hypertension in Venlafaxine-Medicated Patients – Pharmacokinetic Considerations in Prescribing Amlodipine and Ramipril. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 498-501.	0.7	9
150	Duloxetine enters the brain – But why is it not found in the cerebrospinal fluid. <i>Journal of Affective Disorders</i> , 2016, 189, 159-163.	2.0	8
151	Pharmacokinetics of venlafaxine in treatment responders and non-responders: a retrospective analysis of a large naturalistic database. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1109-1116.	0.8	8
152	Cytochrome P450-mediated inhibition of venlafaxine metabolism by trimipramine. <i>International Clinical Psychopharmacology</i> , 2019, 34, 241-246.	0.9	8
153	Pharmacokinetic interactions between clozapine and sertraline in smokers and non-smokers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 127, 303-308.	1.2	8
154	Is Therapeutic Drug Monitoring Relevant for Antidepressant Drug Therapy? Implications From a Systematic Review and Meta-Analysis With Focus on Moderating Factors. <i>Frontiers in Psychiatry</i> , 2022, 13, 826138.	1.3	8
155	Lack of Association of a Functional Catechol-O-Methyltransferase Gene Polymorphism With Risk of Tobacco Smoking: Results From a Multicenter Case-Control Study. <i>Nicotine and Tobacco Research</i> , 2013, 15, 1322-1327.	1.4	7
156	Interaction Between Risperidone, Venlafaxine, and Metronidazole. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 730-733.	0.7	7
157	Pharmacokinetic considerations in antipsychotic augmentation strategies: How to combine risperidone with low-potency antipsychotics. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 76, 101-106.	2.5	7
158	Acute effect of intravenously applied alcohol in the human striatal and extrastriatal D2 /D3 dopamine system. <i>Addiction Biology</i> , 2017, 22, 1449-1458.	1.4	7
159	Prefrontal and striatal dopamine D2/D3 receptors correlate with fMRI BOLD activation during stopping. <i>Brain Imaging and Behavior</i> , 2022, 16, 186-198.	1.1	7
160	Novel Treatment Approaches for Substance Use Disorders: Therapeutic Use of Psychedelics and the Role of Psychotherapy. <i>Current Addiction Reports</i> , 2022, 9, 48-58.	1.6	7
161	The neuroendocrinological profile of roxindole, a dopamine autoreceptor agonist, in schizophrenic patients. <i>Psychopharmacology</i> , 1995, 117, 472-478.	1.5	6
162	Altered benzodiazepine receptor sensitivity in alcoholism: A study with fMRI and acute lorazepam challenge. <i>Psychiatry Research - Neuroimaging</i> , 2007, 154, 241-251.	0.9	6

#	ARTICLE	IF	CITATIONS
163	Neuropsychological Correlates of Transcription Factor AP-2Beta, and Its Interaction with COMT and MAOA in Healthy Females. <i>Neuropsychobiology</i> , 2013, 68, 79-90.	0.9	6
164	Patient-oriented randomisation: A new trial design applied in the Neuroleptic Strategy Study. <i>Clinical Trials</i> , 2016, 13, 251-259.	0.7	6
165	Replication of the association between CHRNA4 rs1044396 and harm avoidance in a large population-based sample. <i>European Neuropsychopharmacology</i> , 2016, 26, 150-155.	0.3	6
166	Psychedelics: A New Treatment Paradigm in Psychiatry?. <i>Pharmacopsychiatry</i> , 2021, 54, 149-150.	1.7	6
167	The negative impact of vitamin D on antipsychotic drug exposure may counteract its potential benefits in schizophrenia. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3193-3200.	1.1	6
168	Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial. <i>Lancet Psychiatry</i> , 2022, 9, 291-306.	3.7	6
169	Pharmacokinetic correlates of venlafaxine: associated adverse reactions. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 851-857.	1.8	5
170	Peripheral Oxytocin Predicts Higher-Level Social Cognition in Men Regardless of Empathy Quotient. <i>Pharmacopsychiatry</i> , 2019, 52, 148-154.	1.7	5
171	Lack of Smoking Effects on Pharmacokinetics of Oral Paliperidone-analysis of a Naturalistic Therapeutic Drug Monitoring Sample. <i>Pharmacopsychiatry</i> , 2021, 54, 31-35.	1.7	5
172	Serotonin and amyloid deposition: A link between depression and Alzheimer's disease?. <i>Journal of Neurochemistry</i> , 2021, 156, 560-562.	2.1	5
173	Prolactin secretion is not a core dimension of 'atypicality'. <i>Psychopharmacology</i> , 2002, 162, 93-93.	1.5	4
174	Clinically relevant changes in clozapine serum concentrations after breast reduction surgery. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 1059-1060.	1.3	4
175	Antidopaminergic medication in healthy subjects provokes subjective and objective mental impairments tightly correlated with perturbation of biogenic monoamine metabolism and prolactin secretion. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 1125-1138.	1.0	4
176	A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 83-94.	1.8	4
177	Changes in Clozapine Bioavailability in a Percutaneous Endoscopic Gastrostomy-Fed Patient With Treatment-Resistant Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 306-308.	0.7	4
178	Treatment Goals for Patients with Schizophrenia - A Narrative Review of Physician and Patient Perspectives. <i>Pharmacopsychiatry</i> , 2021, 54, 53-59.	1.7	4
179	Clinical response in patients treated with once-monthly paliperidone palmitate: analysis of a therapeutic drug monitoring (TDM) database. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021, 271, 1437-1443.	1.8	4
180	The downside of downregulation. <i>Brain</i> , 2019, 142, 1500-1502.	3.7	3

#	ARTICLE	IF	CITATIONS
181	Plasma Levels and Cerebrospinal Fluid Penetration of Venlafaxine in a Patient With a Nonfatal Overdose During a Suicide Attempt. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 398-399.	0.7	2
182	The Effects of Co-prescription of Pantoprazole on the Clozapine Metabolism. <i>Pharmacopsychiatry</i> , 2020, 53, 65-70.	1.7	2
183	Assessment of Psychosocial Functioning in a Large Cohort of Patients with Schizophrenia. <i>Psychiatric Quarterly</i> , 2021, 92, 177-191.	1.1	2
184	Effects of body weight, smoking status, and sex on plasma concentrations of once-monthly paliperidone palmitate. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 243-249.	1.3	2
185	BENZODIAZEPINE-RECEPTORS IN DEPRESSION AND ANXIETY MEASURED BY IOMAZENIL-SPECT. <i>Clinical Neuropharmacology</i> , 1992, 15, 201B.	0.2	1
186	Pharmacokinetic Correlates of Once-Monthly Paliperidone Palmitate-Related Adverse Drug Reactions. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1583-1589.	1.6	1
187	Determination of Drug Concentrations in Serum and Dopamine Receptor Occupancy in Brain for Optimal Antipsychotic Drug Therapy. <i>European Psychiatry</i> , 2009, 24, .	0.1	0
188	Response from the authors. <i>Clinical Trials</i> , 2016, 13, 262-263.	0.7	0
189	Comprehensive measurements of intrauterine and postnatal exposure to lamotrigine. , 2018, 51, .		0
190	The effect of pharmacological interaction between a proton pump inhibitor pantoprazole and clozapine. <i>Pharmacopsychiatry</i> , 2018, 51, .	1.7	0
191	The clinical relevance of the pharmacological interaction between clozapine and sertraline. , 2019, 52, .		0
192	10 How valid are therapeutic reference ranges for psychotropic drugs?. , 2020, 53, .		0
193	P.0693 Escitalopram: Drug monitoring for dose titration? Systematic literature review on the therapeutic and the dose-related reference range. <i>European Neuropsychopharmacology</i> , 2021, 53, S507-S508.	0.3	0
194	P.0421 Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) â€“ study design, rationale and current status. <i>European Neuropsychopharmacology</i> , 2021, 53, S306.	0.3	0
195	Therapeutic reference range for aripiprazole revised: A systematic review and combined analysis. <i>Pharmacopsychiatry</i> , 2022, , .	1.7	0
196	Ketamine Metabolite Plasma Levels as Potential Blood Markers of Ketamine Efficacy in Treatment Resistant Depression. <i>Pharmacopsychiatry</i> , 2022, , .	1.7	0
197	Escitalopram: Drug monitoring for dose titration? Systematic literature review on the therapeutic and the dose-related reference range. <i>Pharmacopsychiatry</i> , 2022, , .	1.7	0
198	How valid are therapeutic reference ranges for psychotropic drugs?. <i>Pharmacopsychiatry</i> , 2022, , .	1.7	0

#	ARTICLE	IF	CITATIONS
199	The therapeutic reference range for olanzapine revised – how to combine old and new findings. Pharmacopsychiatry, 2022, , .	1.7	0
200	Is Therapeutic Drug Monitoring Relevant for Antidepressant Drug Therapy? Implications From a Systematic Review and Meta-Analysis With Focus on Moderating Factors. Pharmacopsychiatry, 2022, , .	1.7	0
201	Case series: Higher antipsychotic drug levels in patients with schizophrenia after COVID-19 vaccination. Pharmacopsychiatry, 2022, , .	1.7	0